Ivermectin in Prevention and Treatment of COVID-19

Efficacy of Ivermectin in Prevention and Treatment of COVID-19: A Randomized-Controlled Study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210929002

Enrollment

1000

Registered

2021-09-29

Start date

2021-08-19

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suspected of SARS-CoV-2 infection SARS-CoV-2 infection, COVID-19, Ivermectin

Interventions

Ivermectin 400-600 micrograms per kilogram body weight daily for 3 days,Placebo drug

Experimental Drug,Placebo Comparator Drug

Ivermectin,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with respiratory tract symptoms or fever, or asymptomatic and contact with confirmed COVID-19 at outpatients clinic 2. Performed nasopharyngeal swab for PCR-COVID on the enrollment date 3. Available for telephone interview 4. Able to sign written informed consent

Exclusion criteria

Exclusion criteria: 1. Previous COVID-19 infection within 90 days before enrollment 2. Pregnancy and/or lactation 3. Allergy to Ivermectin or drugs with gamma-aminobutyric acid (GABA) potentiating activity and/or altered p-glycoprotein transport system

Design outcomes

Primary

Measure	Time frame
Proportion of confirmed COVID-19 by RT-PCR or rapid antigen test Day 14 Percent (became positive RT-PCR or rapid antigen case/ all patients with RT-PCR negative at baseline): analyzed subpopulation based on duration of last contact, BW and vaccination status	—

Secondary

Measure	Time frame
Clinical Progression (WHO Clinical Progression Scale) Day 7, 14 Change in score at each time point from baseline: analyzed subpopulation based on duration of illness, BW, vaccination status and CT value,Desaturation Day 7,14, 28 Percent of patients with desaturation within 14 and 28 days: analyzed subpopulation based on duration of illness, BW, vaccination status and CT value,Hospitalization Days 7, 14, 28 Percent of patients hospitalized due to COVID condition ,All-cause mortality Within 28 days Medical Record Review,Adverse Events Day 3, 7, 14 Telephone Interview,Change of number of symptoms compare to baseline Day 3, 7, 14 number,Absence of all symptoms Day 7 and 14 Proportion	—

Measure

Time frame

Clinical Progression (WHO Clinical Progression Scale) Day 7, 14 Change in score at each time point from baseline: analyzed subpopulation based on duration of illness, BW, vaccination status and CT value,Desaturation Day 7,14, 28 Percent of patients with desaturation within 14 and 28 days: analyzed subpopulation based on duration of illness, BW, vaccination status and CT value,Hospitalization Days 7, 14, 28 Percent of patients hospitalized due to COVID condition ,All-cause mortality Within 28 days Medical Record Review,Adverse Events Day 3, 7, 14 Telephone Interview,Change of number of symptoms compare to baseline Day 3, 7, 14 number,Absence of all symptoms Day 7 and 14 Proportion

—

Countries

Thailand

Contacts

Public ContactNasikarn Angkasekwinai

Faculty of Medicine, Siriraj Hospital

nasikarn.ang@mahidol.ac.th0818708766

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026